From: Measurable residual disease in multiple myeloma: ready for clinical practice?
Study | Treatment | Outcome | MRD assessment | MRD-negative rate |
---|---|---|---|---|
Transplant-eligible | ||||
HDT vs RVD | HDT: median PFS 50m RVD: median PFS 36m | NGS (10−6)a | HDT 30% RVD 20% | |
CASSIOPEIA (NCT02541383) [10] | D-VTd vs VTd | D-VTD: 18m PFS 93% VTD: 18m PFS 85% | NGF (10−5) | D-VTD 64% VTD 44% |
Transplant-ineligible | ||||
ALCYONE (NCT02195479) [25] | D-VMP vs VMP | D-VMP: median PFS NR VMP: median PFS 18.1m | NGS (10−5) | D-VMP 22.3% VMP 6.2% |
CLARION (NCT01818752) [27] | KMP vs VMP | KMP: median PFS 22.3m VMP: median PFS 22.1m | NGF (10−6) | KMP 15.7% VMP 15.5% |
MAIA (NCT02252172) [26] | DRd vs Rd | DRd: median PFS NR Rd: median PFS 31.9m | NGS (10−5) | DRd 24.2% Rd 7.3% |
Relapse/refractory | ||||
POLLUX (NCT02076009) [30] | DRd vs Rd | DRd: median PFS NR Rd: median PFS 17.5m | NGS (10−5) | DRd 22.4% Rd 4.6% |
CASTOR (NCT02136134) [29] | DVd vs Vd | DVd: median PFS 16.7m Vd: median PFS 7.1m | NGS (10−5) | DVd 11.6% Vd 2.4% |